Bulgaria,
December 2017
Squirreled away right on the South-Eastern fringe of Europe, Bulgaria still has a tendency to be overlooked and underestimated by the uninitiated. Not so by the international pharmaceuticals industry, however, which has long considered what is one of the EU’s most recent member states to be a comparatively uncomplicated and hospitable place for doing business; so too an excellent entry point into the Commonwealth of Independent States (CIS) region.
Through interviews with the leaders of multinational affiliates implanted in Bulgaria, enterprising heads of local companies, key opinion leaders, government representatives, and a wealth of service providers, a picture emerges of a country with discernable momentum in healthcare and the life sciences that is fast becoming a regional leader.
Squirreled away right on the South-Eastern fringe of Europe, Bulgaria still has a tendency to be overlooked and underestimated by the uninitiated. Not so by the international pharmaceuticals industry, however, which has long considered what is one of the EU’s most recent member states to be a comparatively uncomplicated and hospitable place for doing business; so too an excellent entry point into the Commonwealth of Independent States (CIS) region.
Through interviews with the leaders of multinational affiliates implanted in Bulgaria, enterprising heads of local companies, key opinion leaders, government representatives, and a wealth of service providers, a picture emerges of a country with discernable momentum in healthcare and the life sciences that is fast becoming a regional leader.
